Forbes |
Antibiotics Are Money-Losers For Big Pharma. How Can We Incentivize The Development Of New Ones?
Forbes The Reinvigorating Antibiotic and Diagnostic Innovation Act would increase R&D tax credits for antibiotic research, but seems to have gone nowhere in the current Congress. But the real issue isn't regulatory approval. That makes a difference only at ... |
January 02, 2018 at 01:20PM | money - Google News
Antibiotics Are Money-Losers For Big Pharma. How Can We Incentivize The Development Of New Ones? - Forbes
money - Google News
money - Google News | January 02, 2018 at 01:20PM | Antibiotics Are Money-Losers For Big Pharma. How Can We Incentivize The Development Of New Ones? - Forbes
Nenhum comentário:
Postar um comentário